This week in Other Barks & Bites: the U.S. Trade Representative issues its annual Special 301 Report listing the European ...
Alnylam Pharmaceuticals is well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset ...
Sun Pharma will acquire Organon for $11.75 billion. Astellas projects Xtandi sales to decline in fiscal year 2026. | Sun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results